Patents by Inventor Juerg F. Tschopp
Juerg F. Tschopp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6521594Abstract: The invention provides cyclic peptides which inhibit platelet aggregation without causing prolonged bleeding time. The invention provides RGD or KGD containing peptides which are cyclized and contain hydrophobic amino acids adjacent to the carboxy terminus of the RGD sequence. Peptides of this nature are also provided which contain in addition to the hydrophobic amino acid an adjacent positively charged amino acid. Such peptides have a high affinity for the receptor IIb/IIIa and a low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis.Type: GrantFiled: May 22, 1995Date of Patent: February 18, 2003Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, Soan Cheng, William S. Craig, Juerg F. Tschopp
-
Patent number: 6395873Abstract: The invention provides cyclic peptides which inhibit platelet aggregation without causing prolonged bleeding time. The invention provides RGD or KGD containing peptides which are cyclized and contain hydrophobic moieties adjacent to the carboxy terminus of the RGD sequence. Peptides of this nature are also provided which contain in addition to the hydrophobic. moiety an adjacent positively charged moiety. Such peptides have a high affinity for the receptor IIb/IIIa and a low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis.Type: GrantFiled: June 1, 1995Date of Patent: May 28, 2002Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, David S. Lukeman, Soan Cheng, William S. Craig, Juerg F. Tschopp
-
Patent number: 6017877Abstract: The invention provides cyclic peptides which inhibit platelet aggregation without causing prolonged bleeding time. The invention provides RGD or KGD containing peptides which are cyclized and contain hydrophobic amino acids adjacent to the carboxy terminus of the RGD sequence. Peptides of this nature are also provided which contain in addition to the hydrophobic amino acid an adjacent positively charged amino acid. Such peptides have a high affinity for the receptor IIb/IIIa and a low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis.Type: GrantFiled: May 19, 1994Date of Patent: January 25, 2000Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, David S. Lukeman, Soan Cheng, William S. Craig, Juerg F. Tschopp
-
Patent number: 5849865Abstract: The present invention provides Arg-Gly-Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg-Gly-Asp peptides to alter .alpha..sub.v .beta..sub.3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.Type: GrantFiled: April 12, 1995Date of Patent: December 15, 1998Assignee: La Jolla Cancer Research FoundationInventors: Soan Cheng, Ronald Ingram, Daniel Mullen, Juerg F. Tschopp
-
Patent number: 5807819Abstract: The present invention provides Arg--Gly--Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg--Gly--Asp peptides to alter .alpha..sub.V .beta..sub.3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.Type: GrantFiled: April 12, 1995Date of Patent: September 15, 1998Assignee: La Jolla Cancer Research CenterInventors: Soan Cheng, Ronald Ingram, Daniel Mullen, Juerg F. Tschopp
-
Patent number: 5792745Abstract: The present invention provides Arg-Gly-Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg-Gly-Asp peptides to alter .alpha..sub.v .beta..sub.3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.Type: GrantFiled: April 12, 1995Date of Patent: August 11, 1998Assignee: La Jolla Cancer Research CenterInventors: Soan Cheng, Ronald Ingram, Daniel Mullen, Juerg F. Tschopp
-
Patent number: 5780303Abstract: A method for identifying a peptide useful for inhibiting platelet aggregation activity without substantially prolonging bleeding time comprising determining the IC.sub.50 value of the peptide in both a heparin assay and a citrate assay and then comparing the value of the IC.sub.50 from each assay.Type: GrantFiled: June 2, 1995Date of Patent: July 14, 1998Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, Soan Cheng, William S. Craig, Juerg F. Tschopp
-
Patent number: 5773412Abstract: The present invention provides Arg--Gly--Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg--Gly--Asp peptides to alter .alpha..sub.v .beta..sub.3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.Type: GrantFiled: April 12, 1995Date of Patent: June 30, 1998Assignee: La Jolla Cancer Research CenterInventors: Soan Cheng, Ronald Ingram, Daniel Mullen, Juerg F. Tschopp
-
Patent number: 5759996Abstract: The present invention provides Arg-Gly-Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg-Gly-Asp peptides to alter .alpha..sub.v .beta..sub.3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.Type: GrantFiled: April 12, 1995Date of Patent: June 2, 1998Assignee: La Jolla Cancer Research CenterInventors: Soan Cheng, Ronald Ingram, Daniel Mullen, Juerg F. Tschopp
-
Patent number: 5707828Abstract: The present invention is directed to expression cassettes comprising a 5' regulatory region from at least one of the Pichia pastoris AOXI gene, p40 gene, DASI gene or HIS4 gene, operably linked to an HSA structural gene including the HSA signal sequence. The HSA structural gene has a translational start codon within 0 to 11 deoxyribonucleotides from the 5' end of the HSA structural gene and is operably linked to a 3' termination sequence. Further, the adenine and thymine content of the intervening deoxyribonucleotides is in the range from about 55 to about 64%. The expression cassette may be an autonomously replicating vector or an integrative vector. Other embodiments of the present invention include Pichia pastoris strains transformed with the HSA expression cassettes and processes for secretion of HSA using the expression cassettes.Type: GrantFiled: May 3, 1995Date of Patent: January 13, 1998Assignee: Research Corporation Technologies, Inc.Inventors: Kotikanyadan Sreekrishna, Juerg F. Tschopp, Gregory P. Thill, Russell A. Brierley, Kathryn A. Barr
-
Patent number: 5672585Abstract: The invention provides cyclic peptides which inhibit platelet aggregation without causing prolonged bleeding time. The invention provides RGD or KGD containing peptides which are cyclized and contain hydrophobic amino acids adjacent to the carboxy terminus of the RGD sequence. Peptides of this nature are also provided which contain in addition to the hydrophobic amino acid an adjacent positively charged amino acid. Such peptides have a high affinity for the receptor IIb/IIIa and a low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis.Type: GrantFiled: May 22, 1995Date of Patent: September 30, 1997Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, Soan Cheng, William S. Craig, Juerg F. Tschopp
-
Patent number: 5612311Abstract: The invention provides cyclic peptides which inhibit platelet aggregation without causing prolonged bleeding time. The invention provides RGD or KGD containing peptides which are cyclized and contain hydrophobic moieties adjacent to the carboxy terminus of the RGD sequence. Peptides of this nature are also provided which contain in addition to the hydrophobic moiety an adjacent positively charged moiety. Such peptides have a high affinity for the receptor IIb/IIIa and a low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis.Type: GrantFiled: December 22, 1994Date of Patent: March 18, 1997Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, David S. Lukeman, Soan Cheng, William S. Craig, Juerg F. Tschopp
-
Patent number: 4895800Abstract: Novel DNA constructs comprising regulatory regions plus the structural coding region for hepatitis B surface antigen (HBsAg) are disclosed. The regulatory regions employed are responsive to methanol, non-catabolite repressing carbon sources and catabolite repressing carbon sources followed by carbon source starvation. The novel constructs are incorporated into a variety of linear and circular plasmids. Such plasmids are used to transform suitable hosts and ultimately used for the production and isolation of hepatitis B surface antigen in high yields.Type: GrantFiled: November 26, 1985Date of Patent: January 23, 1990Assignee: Phillips Petroleum CompanyInventors: Juerg F. Tschopp, Michael M. Harpold, James M. Cregg, Richard G. Buckholz
-
Patent number: 4855231Abstract: Novel DNA sequences which are responsive to the presence of methanol, catabolite non-repressing carbon sources and carbon source starvation are provided. In addition, novel constructs including these DNA sequences, as well as transformed organisms therewith are provided. Processes for producing the DNA sequences and constructs of the invention are detailed. The production of polypeptide product under the control of the regulatory regions of the invention is demonstrated.Type: GrantFiled: September 25, 1985Date of Patent: August 8, 1989Assignee: Phillips Petroleum CompanyInventors: David W. Stroman, Paul F. Brust, Steven B. Ellis, Thomas R. Gingeras, Michael M. Harpold, Juerg F. Tschopp
-
Patent number: 4808537Abstract: A method for isolating and cloning methanol inducible genes from Pichia is taught. The regulatory regions are useful for the methanol regulated expression of heterologous genes.Type: GrantFiled: October 30, 1984Date of Patent: February 28, 1989Assignee: Phillips Petroleum CompanyInventors: David W. Stroman, Paul F. Brust, Steven B. Ellis, Thomas R. Gingeras, Michael M. Harpold, Juerg F. Tschopp